Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06768671 · ClinicalTrials.gov registry record · Phase 3
An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents With Moderate to Severe Hidradenitis Suppurativa (VELA-TEEN)
A Phase 3 study of Hidradenitis Suppurativa, sponsored by MoonLake Immunotherapeutics.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 35
- Enrollment target
- 18
- Study locations
NCT06768671 is a Phase 3 study of Hidradenitis Suppurativa that is actively recruiting participants, run by MoonLake Immunotherapeutics. The registered enrollment target is 35 participants, below the 597-participant average among 52 other Hidradenitis Suppurativa trials with a reported enrollment target (94% lower). The trial reports 18 study locations across 14 states.
The verdict
NCT06768671, a Phase 3 study of Hidradenitis Suppurativa, is actively recruiting participants, sponsored by MoonLake Immunotherapeutics.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 35 participants
- Enrollment target
- 18
- Study locations
Study Summary
This is a study to evaluate the pharmacokinetic (PK) and safety of sonelokimab in adolescent patients with HS.
Conditions Studied
Interventions
- DRUG Sonelokimab
Study Locations (18)
Texas
- Clinical Site - Dallas
- Clinical Site - Dallas
- Clinical Site - San Antonio
Florida
- Clinical Site - Hollywood
- Clinical Site - Miami
Georgia
- Clinical Site - Macon
- Clinical Site - Sandy Springs
Arkansas
- Clinical Site - North Little Rock
California
- Clinical Site - Stanford
District of Columbia
- Clinical Site - Washington D.C.
Illinois
- Clinical Site - Chicago
Indiana
- Clinical Site - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2024-12-30 |
| Est. Completion | 2026-03-27 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06768671
The ClinicalTrials.gov registry entry for NCT06768671 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 597-participant average among 52 other Hidradenitis Suppurativa trials with a reported enrollment target (94% lower). The listed sponsor is MoonLake Immunotherapeutics, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hidradenitis Suppurativa appearing as the primary indexed condition, and to 1 intervention - of which Sonelokimab is the first listed.
NCT06768671 reports 18 study locations spanning 14 distinct geographic areas - top geographies include Texas, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT06768671 about?
NCT06768671 is a clinical study titled "An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents With Moderate to Severe Hidradenitis Suppurativa (VELA-TEEN)". This is a study to evaluate the pharmacokinetic (PK) and safety of sonelokimab in adolescent patients with HS.
What is the current status of trial NCT06768671?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 35 participants. The study started on 2024-12-30. Estimated completion is 2026-03-27.
What conditions does trial NCT06768671 study?
This clinical trial studies the following conditions: Hidradenitis Suppurativa.
What interventions are being tested in trial NCT06768671?
The interventions under investigation include: Sonelokimab (DRUG).
Who is sponsoring clinical trial NCT06768671?
This trial is sponsored by MoonLake Immunotherapeutics, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06768671 being conducted?
This trial has 18 study locations across Arkansas, California, District of Columbia, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hidradenitis Suppurativa
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa
RECRUITING · Phase 3
-
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
RECRUITING · Phase 3
-
Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2)
RECRUITING · Phase 3
-
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy
RECRUITING · Phase 3
-
A Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Adolescents With Moderate to Severe Hidradenitis Suppurativa
RECRUITING · Phase 3
-
Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1)
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.